<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="32feb2f4-2ee5-6219-e063-6394a90a9ef9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Oxybutynin Chloride Extended-Release Tablets USP
 <br/>
Rx Only
 <br/>
      <br/>
These highlights do not include all the information needed to use Oxybutynin chloride extended-release tablets safely and effectively. See full prescribing information for Oxybutynin chloride extended-release tablets.
 <br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
      <br/>
Oxybutynin chloride extended-release tablets for oral use
 <br/>
      <br/>
      <br/>
      <br/>
Initial U.S. Approval: 1975
</title>
   <effectiveTime value="20250417"/>
   <setId root="242b4766-bc2b-0073-d72d-1bf879bbee24"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="832926666"/>
            <name>AvPAK</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="32ff15b7-bbf9-b66f-e063-6294a90a943a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250417"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50268-627" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Oxybutynin Chloride<suffix>Extended Release</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxybutynin Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="62175-270" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3J2P07GVB6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L9F3D9RENQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYBUTYNIN CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K9P6MC7092" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYBUTYNIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50268-627-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="50" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50268-627-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120525"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078503" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120525"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KU;270</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50268-628" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Oxybutynin Chloride<suffix>Extended Release</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxybutynin Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="62175-271" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3J2P07GVB6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L9F3D9RENQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYBUTYNIN CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K9P6MC7092" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYBUTYNIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50268-628-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="50" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50268-628-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120525"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078503" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120525"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KU;271</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50268-629" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Oxybutynin Chloride<suffix>Extended Release</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxybutynin Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="62175-272" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3J2P07GVB6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L9F3D9RENQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYBUTYNIN CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K9P6MC7092" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYBUTYNIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50268-629-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50268-629-13" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120525"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078503" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120525"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KU;272</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_5c1dd76e-f55e-480d-be18-cb69186e9470">
               <id root="7bbf35c4-f801-8640-e053-2a91aa0ab2d0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).</paragraph>
               </text>
               <effectiveTime value="20161003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. 
          
  
     
          
  
     <linkHtml href="#LINK_5c1dd76e-f55e-480d-be18-cb69186e9470">(1) </linkHtml> 

         
 
    
         
 
    </item>
                           <item>Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). 
          
  
     
          
  
     <linkHtml href="#LINK_5c1dd76e-f55e-480d-be18-cb69186e9470">(1)</linkHtml> 
         
 
    
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_c03e779a-68f1-460f-94f2-e306c8b0a0f5">
               <id root="7bbf124f-7a6e-2a12-e053-2a91aa0a940f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed.</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets may be administered with or without food.</paragraph>
               </text>
               <effectiveTime value="20160131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Oxybutynin chloride extended-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. Oxybutynin chloride extended-release tablets may be administered with or without food. 
    <linkHtml href="#LINK_c03e779a-68f1-460f-94f2-e306c8b0a0f5">(2)</linkHtml>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Adults: </content>Start with 5 mg or 10 mg, once daily at approximately the same time every day. Dose should not exceed 30 mg per day. 
     <linkHtml href="#LINK_d4308b1b-b4aa-4a5c-ba0e-b763f1535240">(2.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="bold">Pediatric patients (6 years of age or older): </content>Start with 5 mg, once daily at approximately the same time every day. Dose should not exceed 20 mg per day. 
     <linkHtml href="#LINK_4c3d4322-140c-4ca5-bb46-d60dacdf53bf">(2.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d4308b1b-b4aa-4a5c-ba0e-b763f1535240">
                     <id root="7bbf35c4-f803-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adults</title>
                     <text>
                        <paragraph>The recommended starting dose of Oxybutynin chloride extended-release tablets is 5 or 10 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 30 mg/day). In general, dosage adjustment may proceed at approximately weekly intervals.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4c3d4322-140c-4ca5-bb46-d60dacdf53bf">
                     <id root="7bbf35c4-f804-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pediatric Patients Aged 6 Years of Age and Older</title>
                     <text>
                        <paragraph>The recommended starting dose of Oxybutynin chloride extended-release tablets is 5 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 20 mg/day).</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_71ff881f-811d-433e-bd85-381d4113baec">
               <id root="7bbf35c4-f805-8640-e053-2a91aa0ab2d0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets are available as 5, 10 and 15 mg tablets for oral use:</paragraph>
                  <paragraph>5 mg: White, round, biconvex tablet with "270" printed on one side and "KU" printed on the other side with black ink.</paragraph>
                  <paragraph>10 mg: White, round, biconvex tablet with "271" printed on one side and "KU" printed on the other side with black ink.</paragraph>
                  <paragraph>15 mg: White, round, biconvex tablet with "272" printed on one side and "KU" printed on the other side with black ink.</paragraph>
               </text>
               <effectiveTime value="20160131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended release tablets 5 mg, 10 mg and 15 mg 
         
 
    
         
 
    <linkHtml href="#LINK_71ff881f-811d-433e-bd85-381d4113baec">(3)</linkHtml> 
        

   
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_d9078917-6fd9-4117-b097-40114264916b">
               <id root="7bbf35c4-f806-8640-e053-2a91aa0ab2d0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma.</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. There have been reports of hypersensitivity reactions, including anaphylaxis and angiodema.</paragraph>
               </text>
               <effectiveTime value="20161003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Urinary retention 
          
  
     
          
  
     <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4) </linkHtml>  

         
 
    
         
 
    </item>
                           <item>Gastric Retention 
          
  
     
          
  
     <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4)</linkHtml>   

         
 
    
         
 
    </item>
                           <item>Uncontrolled narrow angle glaucoma 
          
  
     
          
  
     <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4)  </linkHtml> 

         
 
    
         
 
    </item>
                           <item>Known hypersensitivity to Oxybutynin chloride extended-release tablets, oxybutynin or any component of Oxybutynin chloride extended-release tablets 
          
  
     
          
  
     <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4)</linkHtml> 
         
 
    
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_000f6db5-d40d-440e-ad89-b0b7cbe43aa1">
               <id root="7bbf4ed7-54ef-78a7-e053-2991aa0a3309"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20161003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Angioedema: Angioedema has been reported with oxybutynin. If symptoms of angioedema occur, discontinue Oxybutynin chloride extended-release tablets immediately and initiate appropriate therapy. 
     <linkHtml href="#LINK_960067bc-ebbf-43de-a0c2-343b826da999">(5.1)</linkHtml>
                           </item>
                           <item>Central Nervous System (CNS) effects: CNS effects have been reported with oxybutynin. If patient experiences anticholinergic CNS effects, consider dose adjustment or discontinuation of Oxybutynin chloride extended-release tablets. 
     <linkHtml href="#LINK_3a813c53-c2c5-4f1b-a553-46142d9eae57">(5.2)</linkHtml>
                           </item>
                           <item>Use with caution due to aggravation of symptoms:
	
     <list listType="unordered">
                                 <item>Pre-existing dementia in patients treated with cholinesterase inhibitors 
       <linkHtml href="#LINK_3a813c53-c2c5-4f1b-a553-46142d9eae57">(5.2)</linkHtml>
                                 </item>
                                 <item>Parkinson's disease 
       <linkHtml href="#LINK_3a813c53-c2c5-4f1b-a553-46142d9eae57">(5.2)</linkHtml>
                                 </item>
                                 <item>Myasthenia gravis 
       <linkHtml href="#LINK_23a585c3-0f94-461d-bff9-eb695434eecb">(5.3)</linkHtml>
                                 </item>
                                 <item>Decreased gastrointestinal motility in patients with autonomic neuropathy. 
       <linkHtml href="#LINK_7178e378-087e-464a-95bb-3ea00d20778c">(5.4)</linkHtml>
                                 </item>
                              </list>
                           </item>
                           <item>Urinary Retention: Use with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention 
     <linkHtml href="#LINK_8dbc45c5-8b6f-424f-9822-0ddf07ea6365">(5.5)</linkHtml>
                           </item>
                           <item>Gastrointestinal Adverse Reactions: Use with caution in patients with gastrointestinal obstructive disorders or decreased intestinal motility due to risk of gastric retention. Use with caution in patients with gastroesophageal reflux or in patients concurrently taking drugs that can exacerbate esophagitis. 
     <linkHtml href="#LINK_4a59332f-d969-4dfa-a9fa-274625c3c35e">(5.6)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_960067bc-ebbf-43de-a0c2-343b826da999">
                     <id root="7bbf35c4-f808-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1   Angioedema</title>
                     <text>
                        <paragraph>Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3a813c53-c2c5-4f1b-a553-46142d9eae57">
                     <id root="7bbf35c4-f809-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Central Nervous System Effects</title>
                     <text>
                        <paragraph>Oxybutynin is associated with anticholinergic central nervous system (CNS) effects 
         
 
  
         
 
  <content styleCode="italics">[see Adverse Reactions </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_bc1b458e-4e20-44b9-8197-16ed590264d2">(6)]</linkHtml>
                           </content>
                           <linkHtml href="#LINK_bc1b458e-4e20-44b9-8197-16ed590264d2">. </linkHtml> A variety of CNS anticholinergic effects have been reported, including hallucinations, agitation, confusion and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly in the first few months after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how Oxybutynin chloride extended-release tablets affect them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.
        

 
        

 </paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.</paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets should be used with caution in patients with Parkinson's disease due to the risk of aggravation of symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20161003"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_23a585c3-0f94-461d-bff9-eb695434eecb">
                     <id root="7bbf8983-6d10-4c0a-e053-2a91aa0a9876"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Worsening of Symptoms of Myasthenia Gravis</title>
                     <text>
                        <paragraph>Oxybutynin chloride extended-release tablets should be used with caution in patients with myasthenia gravis due to the risk of symptom aggravation.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7178e378-087e-464a-95bb-3ea00d20778c">
                     <id root="7bbf8292-a013-c4f4-e053-2991aa0ad624"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Worsening of Symptoms of Decreased Gastrointestinal Motility in Patients with Autonomic Neuropathy</title>
                     <text>
                        <paragraph>Oxybutynin chloride extended-release tablets should be used with caution in patients with autonomic neuropathy due to the risk of aggravation of symptoms of decreased gastrointestinal motility.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8dbc45c5-8b6f-424f-9822-0ddf07ea6365">
                     <id root="7bbf8983-6d48-4c0a-e053-2a91aa0a9876"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Urinary Retention</title>
                     <text>
                        <paragraph>Oxybutynin chloride extended-release tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention
  <content styleCode="italics"> [see Contraindications 
   <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4)</linkHtml>]. 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161005"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4a59332f-d969-4dfa-a9fa-274625c3c35e">
                     <id root="7bbf8983-6d55-4c0a-e053-2a91aa0a9876"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Gastrointestinal Adverse Reactions</title>
                     <text>
                        <paragraph>Oxybutynin chloride extended-release tablets should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention 
  <content styleCode="italics">[see Contraindications 
   <linkHtml href="#LINK_d9078917-6fd9-4117-b097-40114264916b">(4)</linkHtml>].
  </content>
                        </paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony.</paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.</paragraph>
                        <paragraph>As with any other nondeformable material, caution should be used when administering Oxybutynin chloride extended-release tablets to patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of other drugs in nondeformable controlled-release formulations.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bc1b458e-4e20-44b9-8197-16ed590264d2">
               <id root="32feb284-6991-7fce-e063-6394a90a89bf"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20161005"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common (incidence ≥5%) adverse reactions were dry mouth, constipation, diarrhea, headache, somnolence, and dizziness. 
    <linkHtml href="#LINK_bc1b458e-4e20-44b9-8197-16ed590264d2">(6)</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com </content>
                           <content styleCode="bold">or FDA at 1-800-FDA-1088 or 
     <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_079d1350-477f-43cc-91f8-a19be5df7c03">
                     <id root="7be4387e-9790-29fe-e053-2a91aa0a2b3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The safety and efficacy of Oxybutynin chloride extended-release tablets (5 to 30 mg/day) was evaluated in 774 adult subjects who participated in five double-blind, controlled clinical trials. In four of the five studies, Oxybutynin chloride IR (5 to 20 mg/day in 199 subjects) was an active comparator. Adverse reactions reported by ≥ 1% of subjects are shown in Table 1.</paragraph>
                        <table>
                           <caption>Table 1: Adverse Drug Reactions Reported by ≥ 1% of Oxybutynin chloride extended-release tablets-treated Adult Subjects in Five Double-blind, Controlled Clinical Trials of Oxybutynin chloride extended-release tablets</caption>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule          Rrule     ">System/Organ Class
     <br/>
                                    <br/>
			Preferred Term
    </th>
                                 <th align="center" styleCode="Rrule     ">Oxybutynin chloride extended-release tablets
     <br/>
                                    <br/>
			5 to 30 mg/day
     <br/>
                                    <br/>
			n = 774
     <br/>
                                    <br/>
			%
    </th>
                                 <th align="center" styleCode="Rrule     ">Oxybutynin chloride IR 
     <footnote ID="FOOT_5419">IR = immediate release</footnote>
                                    <br/>
                                    <br/>
			5 to 20 mg/day
     <br/>
                                    <br/>
			n = 199
     <br/>
                                    <br/>
			%
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Psychiatric Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Insomnia</td>
                                 <td align="center" styleCode="Rrule     "> 3.0</td>
                                 <td align="center" styleCode="Rrule     "> 5.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Headache</td>
                                 <td align="center" styleCode="Rrule     "> 7.5</td>
                                 <td align="center" styleCode="Rrule     "> 8.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Somnolence</td>
                                 <td align="center" styleCode="Rrule     "> 5.6</td>
                                 <td align="center" styleCode="Rrule     "> 14.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dizziness</td>
                                 <td align="center" styleCode="Rrule     "> 5.0</td>
                                 <td align="center" styleCode="Rrule     "> 16.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dysgeusia</td>
                                 <td align="center" styleCode="Rrule     "> 1.6</td>
                                 <td align="center" styleCode="Rrule     "> 1.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Eye Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Vision blurred</td>
                                 <td align="center" styleCode="Rrule     "> 4.3</td>
                                 <td align="center" styleCode="Rrule     "> 9.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dry eye</td>
                                 <td align="center" styleCode="Rrule     "> 3.1</td>
                                 <td align="center" styleCode="Rrule     "> 2.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Cough</td>
                                 <td align="center" styleCode="Rrule     "> 1.9</td>
                                 <td align="center" styleCode="Rrule     "> 3.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Oropharyngeal pain</td>
                                 <td align="center" styleCode="Rrule     "> 1.9</td>
                                 <td align="center" styleCode="Rrule     "> 1.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dry throat</td>
                                 <td align="center" styleCode="Rrule     "> 1.7</td>
                                 <td align="center" styleCode="Rrule     "> 2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Nasal dryness</td>
                                 <td align="center" styleCode="Rrule     "> 1.7</td>
                                 <td align="center" styleCode="Rrule     "> 4.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dry mouth</td>
                                 <td align="center" styleCode="Rrule     "> 34.9</td>
                                 <td align="center" styleCode="Rrule     "> 72.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Constipation</td>
                                 <td align="center" styleCode="Rrule     "> 8.7</td>
                                 <td align="center" styleCode="Rrule     "> 15.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Diarrhea</td>
                                 <td align="center" styleCode="Rrule     "> 7.9</td>
                                 <td align="center" styleCode="Rrule     "> 6.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dyspepsia</td>
                                 <td align="center" styleCode="Rrule     "> 4.5</td>
                                 <td align="center" styleCode="Rrule     "> 6.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Nausea</td>
                                 <td align="center" styleCode="Rrule     "> 4.5</td>
                                 <td align="center" styleCode="Rrule     "> 11.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Abdominal pain</td>
                                 <td align="center" styleCode="Rrule     "> 1.6</td>
                                 <td align="center" styleCode="Rrule     "> 2.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Vomiting</td>
                                 <td align="center" styleCode="Rrule     "> 1.3</td>
                                 <td align="center" styleCode="Rrule     "> 1.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Flatulence</td>
                                 <td align="center" styleCode="Rrule     "> 1.2</td>
                                 <td align="center" styleCode="Rrule     "> 2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Gastro-esophageal reflux disease</td>
                                 <td align="center" styleCode="Rrule     "> 1.0</td>
                                 <td align="center" styleCode="Rrule     "> 0.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dry skin</td>
                                 <td align="center" styleCode="Rrule     "> 1.8</td>
                                 <td align="center" styleCode="Rrule     "> 2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Pruritus</td>
                                 <td align="center" styleCode="Rrule     "> 1.3</td>
                                 <td align="center" styleCode="Rrule     "> 1.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Renal and Urinary Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Dysuria</td>
                                 <td align="center" styleCode="Rrule     "> 1.9</td>
                                 <td align="center" styleCode="Rrule     "> 2.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Urinary hesitation</td>
                                 <td align="center" styleCode="Rrule     "> 1.9</td>
                                 <td align="center" styleCode="Rrule     "> 8.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Urinary retention</td>
                                 <td align="center" styleCode="Rrule     "> 1.2</td>
                                 <td align="center" styleCode="Rrule     "> 3.0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Fatigue</td>
                                 <td align="center" styleCode="Rrule     "> 2.6</td>
                                 <td align="center" styleCode="Rrule     "> 3.0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule          Rrule     ">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule          Rrule     ">   Residual urine volume 
     <footnote ID="FOOT_5420">The bundled term residual urine volume consists of the preferred terms residual urine volume and residual urine volume increased.</footnote>
                                 </td>
                                 <td align="center" styleCode="Rrule     "> 2.3</td>
                                 <td align="center" styleCode="Rrule     "> 3.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The discontinuation rate due to adverse reactions was 4.4% with Oxybutynin chloride extended-release tablets compared to 0% with Oxybutynin chloride IR. The most frequent adverse reaction causing discontinuation of study medication was dry mouth (0.7% ).</paragraph>
                        <paragraph>The following adverse reactions were reported by &lt;1% of Oxybutynin chloride extended-release tablets-treated patients and at a higher incidence than placebo in clinical trials: 
  <content styleCode="italics">Metabolism and Nutrition Disorders:</content> anorexia, fluid retention; 
  <content styleCode="italics">Vascular disorders:</content> hot flush; 
  <content styleCode="italics">Respiratory, thoracic and mediastinal disorders:</content> dysphonia; 
  <content styleCode="italics">Gastrointestinal Disorders:</content> dysphagia, frequent bowel movements; 
  <content styleCode="italics">General disorders and administration site conditions:</content> chest discomfort, thirst.
 </paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_83cecc4c-89e9-403b-8b57-7cb5db87be82">
                     <id root="32febb1b-dd12-68f3-e063-6394a90acf77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been reported from worldwide postmarketing experience with Oxybutynin chloride extended-release tablets. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations:</content> Urinary tract infection; 
  <content styleCode="italics">Psychiatric Disorders:</content> psychotic disorder, agitation, confusional state, hallucinations, memory impairment; 
  <content styleCode="italics">Nervous System Disorders:</content> convulsions; 
  <content styleCode="italics">Eye Disorders:</content> glaucoma; 
  <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders:</content> nasal congestion; 
  <content styleCode="italics">Cardiac Disorders:</content> arrhythmia, tachycardia, palpitations; QT interval prolongation; 
  <content styleCode="italics">Vascular Disorders:</content> flushing, hypertension; 
  <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> rash; 
  <content styleCode="italics">Renal and Urinary Disorders:</content> impotence; 
  <content styleCode="italics"> General Disorders and Administration Site Conditions:</content> hypersensitivity reactions, including angioedema with airway obstruction, urticaria, and face edema; anaphylactic reactions requiring hospitalization for emergency treatment; 
  <content styleCode="italics">Injury, poisoning and procedural complications:</content> fall.
 </paragraph>
                        <paragraph>Additional adverse events reported with some other oxybutynin chloride formulations include: cycloplegia, mydriasis, and suppression of lactation.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161005"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_903211c5-c479-4135-80e1-c3761dc7d5de">
               <id root="7bbf35c4-f811-8640-e053-2a91aa0ab2d0"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.</paragraph>
                  <paragraph>Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.</paragraph>
                  <paragraph>Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when Oxybutynin chloride extended-release tablets were administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., C
       
 
  
       
 
  <sub>max</sub> and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20161005"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. 
          
  
     
          
  
     <linkHtml href="#LINK_903211c5-c479-4135-80e1-c3761dc7d5de">(7) </linkHtml> 

         
 
    
         
 
    </item>
                           <item>Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. 
          
  
     
          
  
     <linkHtml href="#LINK_903211c5-c479-4135-80e1-c3761dc7d5de">(7)</linkHtml> 
         
 
    
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_b1459473-6f9a-4f3d-82fb-9e47e8967b08">
               <id root="7bbf7b89-b39b-a841-e053-2991aa0a58e9"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20181128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pediatric Use: Oxybutynin chloride extended-release tablets are not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing or crushing, or in children under the age of 6 years. 
     <linkHtml href="#LINK_901a823f-d5de-4bb9-ad8b-a110693adf78">(8.4)</linkHtml>
                           </item>
                           <item>Renal or Hepatic Impairment: There have been no studies conducted in patients with renal or hepatic impairment. 
     <linkHtml href="#LINK_b283ff08-8098-474a-9eec-380afe51fa52">(8.6,</linkHtml>
                              <linkHtml href="#LINK_9b5c830b-057c-4390-bb4a-d6cdd2bb44be">8.7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d961c140-49bd-40d7-9606-7f8a69540830">
                     <id root="7bbf35c4-f813-8640-e053-2a91aa0ab2d0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20160131"/>
                     <component>
                        <section ID="LINK_1344e026-f598-4ba2-a6a4-c5401497e2d2">
                           <id root="7bbf35c4-f814-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Pregnancy Category B. There are no adequate and well-controlled studies using Oxybutynin chloride extended-release tablets in pregnant women. Oxybutynin chloride extended-release tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. Women who become pregnant during Oxybutynin chloride extended-release tablets treatment are encouraged to contact their physician.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_562cfb92-060b-4db7-aaa8-b7dd43b7913f">
                           <id root="7bbf35c4-f815-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Risk Summary</paragraph>
                              <paragraph>Based on animal data, oxybutynin is predicted to have a low probability of increasing the risk of adverse developmental effects above background risk.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_60610645-72a6-412d-b501-551eea955bfa">
                           <id root="7bbf35c4-f816-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Animal Data</paragraph>
                              <paragraph>Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility or harm to the animal fetus.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e8f56133-3b10-40f3-ad45-bc2418ac574a">
                     <id root="7bbfa16d-3c1b-98a4-e053-2a91aa0a40d7"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Oxybutynin chloride extended-release tablets are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20161005"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_901a823f-d5de-4bb9-ad8b-a110693adf78">
                     <id root="7bbfa7e6-fd25-4750-e053-2991aa0a0d1a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of Oxybutynin chloride extended-release tablets were studied in 60 children in a 24-week, open-label, non-randomized trial. Patients were aged 6–15 years, all had symptoms of detrusor overactivity in association with a neurological condition (e.g., spina bifida), all used clean intermittent catheterization, and all were current users of oxybutynin chloride. Study results demonstrated that administration of Oxybutynin chloride extended-release tablets 5 to 20 mg/day was associated with an increase from baseline in mean urine volume per catheterization from 108 mL to 136 mL, an increase from baseline in mean urine volume after morning awakening from 148 mL to 189 mL, and an increase from baseline in the mean percentage of catheterizations without a leaking episode from 34% to 51%.</paragraph>
                        <paragraph>Urodynamic results were consistent with clinical results. Administration of Oxybutynin chloride extended-release tablets resulted in an increase from baseline in mean maximum cystometric capacity from 185 mL to 254 mL, a decrease from baseline in mean detrusor pressure at maximum cystometric capacity from 44 cm H
  <sub>2</sub>O to 33 cm H
  <sub>2</sub>O, and a reduction in the percentage of patients demonstrating uninhibited detrusor contractions (of at least 15 cm H
  <sub>2</sub>O) from 60% to 28%.
 </paragraph>
                        <paragraph>The pharmacokinetics of Oxybutynin chloride extended-release tablets in these patients were consistent with those reported for adults 
  <content styleCode="italics">[see Clinical Pharmacology 
   <linkHtml href="#LINK_3bda3cff-70a6-4de3-b4da-aeb590e3c379">(12.3)</linkHtml>].
  </content>
                        </paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets are not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing, or crushing, or in children under the age of 6.</paragraph>
                     </text>
                     <effectiveTime value="20161003"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_573f8f9a-926d-479b-8a74-9b5091902428">
                     <id root="7bbf35c4-f819-8640-e053-2a91aa0ab2d0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>The rate and severity of anticholinergic effects reported by patients less than 65 years old and those 65 years and older were similar. The pharmacokinetics of Oxybutynin chloride extended-release tablets were similar in all patients studied (up to 78 years of age).</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b283ff08-8098-474a-9eec-380afe51fa52">
                     <id root="7bbf35c4-f81a-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>There were no studies conducted with Oxybutynin chloride extended-release tablets in patients with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9b5c830b-057c-4390-bb4a-d6cdd2bb44be">
                     <id root="7bbf35c4-f81b-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>There were no studies conducted with Oxybutynin chloride extended-release tablets in patients with hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ca6f786-7d9d-4282-a2c3-f3b23b20fe87">
               <id root="7bbf35c4-f81c-8640-e053-2a91aa0ab2d0"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The continuous release of oxybutynin from Oxybutynin chloride extended-release tablets should be considered in the treatment of overdosage. Patients should be monitored for at least 24 hours. Treatment should be symptomatic and supportive. Activated charcoal as well as a cathartic may be administered.</paragraph>
                  <paragraph>Overdosage with oxybutynin chloride has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention.</paragraph>
                  <paragraph>Ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old boy who experienced memory loss, and a 34-year-old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients fully recovered with symptomatic treatment.</paragraph>
               </text>
               <effectiveTime value="20160131"/>
            </section>
         </component>
         <component>
            <section ID="LINK_88150b83-58ec-4f94-a74c-eabf1f5ec1ca">
               <id root="7bbf35c4-f81d-8640-e053-2a91aa0ab2d0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets are an antispasmodic, muscarinic antagonist. Each Oxybutynin chloride extended-release tablets contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.</paragraph>
                  <paragraph>Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C
       
 
  
       
 
  <sub>22</sub>H
       
 
  
       
 
  <sub>31</sub>NO
       
 
  
       
 
  <sub>3</sub>•HCl.
      

 
      

 </paragraph>
                  <paragraph>Its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets also contain the following inert ingredients: lactose, mannitol, dextrose, tartaric acid, colloidal silicon dioxide, magnesium stearate, cellulose acetate, polyethylene glycol, titanium dioxide, triacetin, black iron oxide, propylene glycol, hypromellose.</paragraph>
               </text>
               <effectiveTime value="20161005"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="oxybutynin-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="LINK_fdaf0a76-2db4-4873-ab7b-218eccd203b4">
                     <id root="7bbf35c4-f81e-8640-e053-2a91aa0ab2d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>System Components and Performance</paragraph>
                        <paragraph>Oxybutynin chloride extended-release tablets uses osmotic pressure to deliver oxybutynin chloride at a controlled rate over approximately 24 hours.  The system, which resembles a conventional tablet in appearance, comprises an osmotically active core surrounded by a semipermeable membrane.  The unitary tablet core is composed of the drug and excipients (including the osmotically active components).  There is a precision-laser drilled orifice in the semipermeable membrane on the side of the tablet.  In an aqueous environment, such as the gastrointestinal tract, water permeates through the membrane into the tablet core, causing the drug to go into suspension and the osmotic components to expand.  This expansion pushes the drug out through the orifice.  The semipermeable membrane controls the rate at which water permeates into the tablet core, which in turn controls the rate of drug delivery.  The controlled rate of drug delivery into the gastrointestinal lumen is thus independent of pH or gastrointestinal motility.  The function of Oxybutynin chloride extended-release tablets depends on the existence of an osmotic gradient between the contents of the core and the fluid in the gastrointestinal tract.  Since the osmotic gradient remains constant, drug delivery remains essentially constant.  The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the feces as an insoluble shell.</paragraph>
                        <paragraph>USP Drug Release Test 3.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_66134faf-24e0-4769-98c4-f2d37de50060">
               <id root="7bbf35c4-f81f-8640-e053-2a91aa0ab2d0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160131"/>
               <component>
                  <section ID="LINK_abcd5d49-c32c-4a6a-a16c-51d127dd7e71">
                     <id root="7bbf35c4-f820-8640-e053-2a91aa0ab2d0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Oxybutynin relaxes bladder smooth muscle. Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).</paragraph>
                        <paragraph>Antimuscarinic activity resides predominantly in the R-isomer. A metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin in 
         
 
  
         
 
  <content styleCode="italics">in vitro</content> studies.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9d96e56f-43a7-4850-9d8e-552a4cd1da49">
                     <id root="7bbf35c4-f821-8640-e053-2a91aa0ab2d0"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3bda3cff-70a6-4de3-b4da-aeb590e3c379">
                     <id root="7bbf35c4-f822-8640-e053-2a91aa0ab2d0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20160131"/>
                     <component>
                        <section ID="LINK_f8876578-42b1-4ea7-bb65-31804fe115b1">
                           <id root="7be41481-f178-f23a-e053-2991aa0a41d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Absorption</paragraph>
                              <paragraph>Following the first dose of Oxybutynin chloride extended-release tablets, oxybutynin plasma concentrations rise for 4 to 6 hours; thereafter steady concentrations are maintained for up to 24 hours, minimizing fluctuations between peak and trough concentrations associated with oxybutynin.</paragraph>
                              <paragraph>The relative bioavailabilities of R- and S-oxybutynin from Oxybutynin chloride extended-release tablets are 156% and 187%, respectively, compared with oxybutynin. The mean pharmacokinetic parameters for R- and S-oxybutynin are summarized in Table 2. The plasma concentration-time profiles for R- and S-oxybutynin are similar in shape; Figure 1 shows the profile for R-oxybutynin.</paragraph>
                              <table>
                                 <caption>Table 2: Mean (SD) R- and S-Oxybutynin Pharmacokinetic Parameters Following a Single Dose of Oxybutynin chloride extended-release tablets 10 mg (n=43)</caption>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule     ">Parameters (units)</th>
                                       <th colspan="2" styleCode="Rrule     ">R-Oxybutynin</th>
                                       <th colspan="2" styleCode="Rrule     ">S-Oxybutynin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule     "> C 
     <sub>max</sub> (ng/mL)
    </td>
                                       <td> 1.0</td>
                                       <td styleCode="Rrule     "> (0.6)</td>
                                       <td> 1.8</td>
                                       <td styleCode="Rrule     "> (1.0)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> T 
     <sub>max</sub> (h)
    </td>
                                       <td> 12.7</td>
                                       <td styleCode="Rrule     "> (5.4)</td>
                                       <td> 11.8</td>
                                       <td styleCode="Rrule     "> (5.3)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> t 
     <sub>1/2</sub> (h)
    </td>
                                       <td> 13.2</td>
                                       <td styleCode="Rrule     "> (6.2)</td>
                                       <td> 12.4</td>
                                       <td styleCode="Rrule     "> (6.1)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> AUC 
     <sub>(0–48)</sub> (ng∙h/mL)
    </td>
                                       <td> 18.4</td>
                                       <td styleCode="Rrule     "> (10.3)</td>
                                       <td> 34.2</td>
                                       <td styleCode="Rrule     "> (16.9)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> AUC 
     <sub>inf</sub> (ng∙h/mL)
    </td>
                                       <td> 21.3</td>
                                       <td styleCode="Rrule     "> (12.2)</td>
                                       <td> 39.5</td>
                                       <td styleCode="Rrule     "> (21.2)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Mean R-oxybutynin plasma concentrations following a single dose of Oxybutynin chloride extended-release tablets 10 mg and oxybutynin 5 mg administered every 8 hours (n=23 for each treatment).</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                              <paragraph>Steady state oxybutynin plasma concentrations are achieved by Day 3 of repeated Oxybutynin chloride extended-release tablets dosing, with no observed drug accumulation or change in oxybutynin and desethyloxybutynin pharmacokinetic parameters.</paragraph>
                              <paragraph>Oxybutynin chloride extended-release tablets steady state pharmacokinetics were studied in 19 children aged 5–15 years with detrusor overactivity associated with a neurological condition (e.g., spina bifida). The children were on Oxybutynin chloride extended-release tablets total daily dose ranging from 5 to 20 mg (0.10 to 0.77 mg/kg). Sparse sampling technique was used to obtain serum samples. When all available data are normalized to an equivalent of 5 mg per day of Oxybutynin chloride extended-release tablets, the mean pharmacokinetic parameters derived for R- and S-oxybutynin and R- and S-desethyloxybutynin are summarized in Table 3. The plasma-time concentration profiles for R- and S-oxybutynin are similar in shape; Figure 2 shows the profile for R-oxybutynin when all available data are normalized to an equivalent of 5 mg per day.</paragraph>
                              <table>
                                 <caption>Table 3: Mean ± SD R- and S-Oxybutynin and R- and S-Desethyloxybutynin Pharmacokinetic Parameters in Children Aged 5–15 Following Administration of 5 to 20 mg Oxybutynin chloride extended-release tablets Once Daily (n=19), All Available Data Normalized to an Equivalent of Oxybutynin chloride extended-release tablets 5 mg Once Daily</caption>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule          Rrule     "/>
                                       <th>R-Oxybutynin</th>
                                       <th styleCode="Rrule     ">S-Oxybutynin</th>
                                       <th styleCode="Rrule     ">R- Desethyloxybutynin</th>
                                       <th styleCode="Rrule     ">S- Desethyloxybutynin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule     "> C 
     <sub>max</sub> (ng/mL)
    </td>
                                       <td styleCode="Lrule     "> 0.7 ± 0.4</td>
                                       <td styleCode="Lrule     "> 1.3 ± 0.8</td>
                                       <td styleCode="Lrule     "> 7.8 ± 3.7</td>
                                       <td styleCode="Lrule          Rrule     "> 4.2 ± 2.3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> T 
     <sub>max</sub> (h)
    </td>
                                       <td styleCode="Lrule     "> 5.0</td>
                                       <td styleCode="Lrule     "> 5.0</td>
                                       <td styleCode="Lrule     "> 5.0</td>
                                       <td styleCode="Lrule          Rrule     "> 5.0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule     "> AUC (ng∙h/mL)</td>
                                       <td styleCode="Lrule     "> 12.8 ± 7.0</td>
                                       <td styleCode="Lrule     "> 23.7 ± 14.4</td>
                                       <td styleCode="Lrule     "> 125.1 ± 66.7</td>
                                       <td styleCode="Lrule          Rrule     "> 73.6 ± 47.7</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 2: Mean steady state (± SD) R-oxybutynin plasma concentrations following administration of 5 to 20 mg Oxybutynin chloride extended-release tablets once daily in children aged 5–15. Plot represents all available data normalized to an equivalent of Oxybutynin chloride extended-release tablets 5 mg once daily.</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM3"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 1</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="oxybutynin-2.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 2</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="oxybutynin-3.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <section ID="LINK_54db4586-47ce-4658-bf5f-e6c661513996">
                                 <id root="7bbf35c4-f824-8640-e053-2a91aa0ab2d0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Food Effects</content>
                                    </paragraph>
                                    <paragraph>The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.</paragraph>
                                 </text>
                                 <effectiveTime value="20160131"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_2f943989-ca7a-44a2-8170-6c4416a501a9">
                           <id root="7bbf35c4-f825-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Distribution</paragraph>
                              <paragraph>Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride. Both enantiomers of oxybutynin are highly bound (&gt;99%) to plasma proteins. Both enantiomers of N-desethyloxybutynin are also highly bound (&gt;97%) to plasma proteins. The major binding protein is alpha-1 acid glycoprotein.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_190e7baf-e08f-411b-8adf-0b81b62b863e">
                           <id root="7bbf35c4-f826-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Metabolism</paragraph>
                              <paragraph>Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active. Following Oxybutynin chloride extended-release tablets administration, plasma concentrations of R- and S-desethyloxybutynin are 73% and 92%, respectively, of concentrations observed with oxybutynin.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ce24fb5f-fa64-41f0-b303-d0646cea9da1">
                           <id root="7bbf35c4-f827-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Excretion</paragraph>
                              <paragraph>Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite desethyloxybutynin.</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_d20b93a4-87b5-40a7-879a-d45114e55023">
                           <id root="7bbf35c4-f828-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Dose Proportionality</paragraph>
                              <paragraph>Pharmacokinetic parameters of oxybutynin and desethyloxybutynin (C
           
 
  
           
 
  <sub>max</sub> and AUC) following administration of 5–20 mg of Oxybutynin chloride extended-release tablets are dose proportional.
          

 
          

 </paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_2534dae6-8ce6-47aa-afd4-8a7fa62c3316">
                           <id root="7bbf35c4-f829-8640-e053-2a91aa0ab2d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>Use in Specific Populations</paragraph>
                           </text>
                           <effectiveTime value="20160131"/>
                           <component>
                              <section ID="LINK_f35ff50e-96cd-4105-abba-ac25f6ed32ba">
                                 <id root="7bbf35c4-f82a-8640-e053-2a91aa0ab2d0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of Oxybutynin chloride extended-release tablets were evaluated in 19 children aged 5–15 years with detrusor overactivity associated with a neurological condition (e.g., spina bifida). The pharmacokinetics of Oxybutynin chloride extended-release tablets in these pediatric patients were consistent with those reported for adults (see Tables 2 and 3, and Figures 1 and 2 above).</paragraph>
                                 </text>
                                 <effectiveTime value="20160131"/>
                              </section>
                           </component>
                           <component>
                              <section ID="LINK_30060b38-77ea-43d9-a3a7-d0225ab47e89">
                                 <id root="7bbf35c4-f82b-8640-e053-2a91aa0ab2d0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gender</content>
                                    </paragraph>
                                    <paragraph>There are no significant differences in the pharmacokinetics of oxybutynin in healthy male and female volunteers following administration of Oxybutynin chloride extended-release tablets.</paragraph>
                                 </text>
                                 <effectiveTime value="20160131"/>
                              </section>
                           </component>
                           <component>
                              <section ID="LINK_689b438e-352e-44fc-a499-f0705f1a3131">
                                 <id root="7bbf35c4-f82c-8640-e053-2a91aa0ab2d0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race</content>
                                    </paragraph>
                                    <paragraph>Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on race in healthy volunteers following administration of Oxybutynin chloride extended-release tablets.</paragraph>
                                 </text>
                                 <effectiveTime value="20160131"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_20fb6983-fb1e-42b4-9857-7ab7bca4ad66">
               <id root="7bbf35c4-f82d-8640-e053-2a91aa0ab2d0"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160131"/>
               <component>
                  <section ID="LINK_1c720fa5-6de6-4ad6-9e3a-db5a5ad73814">
                     <id root="7bbf35c4-f82e-8640-e053-2a91aa0ab2d0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>A 24-month study in rats at dosages of oxybutynin chloride of 20, 80, and 160 mg/kg/day showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum human exposure, based on a human equivalent dose taking into account normalization of body surface area.</paragraph>
                        <paragraph>Oxybutynin chloride showed no increase of mutagenic activity when tested in 
         
 
  
         
 
  <content styleCode="italics">Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae</content>, and 
         
 
  
         
 
  <content styleCode="italics">Salmonella typhimurium</content> test systems.
        

 
        

 </paragraph>
                        <paragraph>Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_54832037-26ee-4f64-8cce-b0760b9b981c">
               <id root="7be417cb-e795-474e-e053-2991aa0a3e5c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets were evaluated for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in three controlled efficacy studies. The majority of patients were Caucasian (89.0%) and female (91.9%) with a mean age of 59 years (range, 18 to 98 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge) as evidenced by ≥ 6 urge incontinence episodes per week and ≥ 10 micturitions per day. Study 1 was a fixed-dose escalation design, whereas the other two studies used a dose-adjustment design in which each patient's final dose was adjusted to a balance between improvement of incontinence symptoms and tolerability of side effects. All three studies included patients known to be responsive to oxybutynin or other anticholinergic medications, and these patients were maintained on a final dose for up to 2 weeks.</paragraph>
                  <paragraph>The efficacy results for the three controlled trials are presented in the following tables and figures.</paragraph>
                  <table>
                     <caption>Number of Urge Urinary Incontinence Episodes Per Week</caption>
                     <thead>
                        <tr>
                           <th styleCode="Lrule     " valign="top">Study 1</th>
                           <th align="center">n</th>
                           <th align="center">Oxybutynin chloride extended-release tablets</th>
                           <th align="center">n</th>
                           <th align="center" styleCode="Rrule     ">Placebo</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean Baseline</td>
                           <td align="center"> 34</td>
                           <td align="center"> 15.9</td>
                           <td align="center"> 16</td>
                           <td align="center" styleCode="Rrule     "> 20.9</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean (SD) Change from Baseline 
     <footnote ID="FOOT_5421">Covariate adjusted mean with missing observations set to baseline values</footnote>
                           </td>
                           <td align="center"> 34</td>
                           <td align="center"> -15.8 (8.9)</td>
                           <td align="center"> 16</td>
                           <td align="center" styleCode="Rrule     "> -7.6 (8.6)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> 95% Confidence Interval for Difference</td>
                           <td align="center" colspan="4" styleCode="Rrule     "> (-13.6, -2.8) 
     <footnote ID="FOOT_5422">The difference between Oxybutynin chloride extended-release tabletsand placebo was statistically significant.</footnote>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule          Rrule     " valign="top"> (Oxybutynin chloride extended-release tablets- Placebo)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <table>
                     <thead>
                        <tr>
                           <th styleCode="Lrule     " valign="top">Study 2</th>
                           <th align="center">n</th>
                           <th align="center">Oxybutynin chloride extended-release tablets</th>
                           <th align="center">n</th>
                           <th align="center" styleCode="Rrule     ">oxybutynin</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean Baseline</td>
                           <td align="center"> 53</td>
                           <td align="center"> 27.6</td>
                           <td align="center"> 52</td>
                           <td align="center" styleCode="Rrule     "> 23.0</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean (SD) Change from Baseline 
     <footnote ID="FOOT_5423">Covariate adjusted mean with missing observations set to baseline values</footnote>
                           </td>
                           <td align="center"> 53</td>
                           <td align="center"> -17.6 (11.9)</td>
                           <td align="center"> 52</td>
                           <td align="center" styleCode="Rrule     "> -19.4 (11.9)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> 95% Confidence Interval for Difference</td>
                           <td align="center" colspan="4" styleCode="Rrule     "> (-2.8, 6.5)</td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule          Rrule     " valign="top"> (Oxybutynin chloride extended-release tablets- oxybutynin)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
                  <table>
                     <thead>
                        <tr>
                           <th styleCode="Lrule     " valign="top">Study 3</th>
                           <th align="center">n</th>
                           <th align="center">Oxybutynin chloride extended-release tablets</th>
                           <th align="center">n</th>
                           <th align="center" styleCode="Rrule     ">oxybutynin</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean Baseline</td>
                           <td align="center"> 111</td>
                           <td align="center"> 18.9</td>
                           <td align="center"> 115</td>
                           <td align="center" styleCode="Rrule     "> 19.5</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> Mean (SD) Change from Baseline 
     <footnote ID="FOOT_5424">Covariate adjusted mean with missing observations set to baseline values</footnote>
                           </td>
                           <td align="center"> 111</td>
                           <td align="center"> -14.5 (8.7)</td>
                           <td align="center"> 115</td>
                           <td align="center" styleCode="Rrule     "> -13.8 (8.6)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule     " valign="top"> 95% Confidence Interval for Difference</td>
                           <td align="center" colspan="4" styleCode="Rrule     "> (-3.0, 1.6) 
     <footnote ID="FOOT_5425">The difference between Oxybutynin chloride extended-release tabletsand oxybutynin fulfilled the criteria for comparable efficacy.</footnote>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule          Rrule     " valign="top"> (Oxybutynin chloride extended-release tablets- oxybutynin)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM6"/>
                  </paragraph>
               </text>
               <effectiveTime value="20161003"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="oxybutynin-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="oxybutynin-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="oxybutynin-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0f9e90cd-c8f9-40b0-b3ba-d0dad784c62b">
               <id root="32ff0f8f-a8ef-b15d-e063-6294a90a27e3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Oxybutynin chloride extended-release tablets 5 mg are round, biconvex, white coated tablets imprinted in black ink with "270" on one side and "KU" on the other side.</paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>NDC 50268-627-15 (10 Tablets per card, 5 cards per carton)</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets 10 mg are round, biconvex, white coated tablets imprinted in black ink with "271" on one side and "KU" on the other side.</paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>NDC 50268-628-15 (10 Tablets per card, 5 cards per carton)</paragraph>
                  <paragraph>Oxybutynin chloride extended-release tablets 15 mg are round, biconvex, white coated tablets imprinted in black ink with "272" on one side and "KU" on the other side.</paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>NDC 50268-629-13 (10 Tablets per card, 3 cards per carton)</paragraph>
                  <paragraph>Dispensed in Unit Dose package. For Institutional Use Only.</paragraph>
               </text>
               <effectiveTime value="20160131"/>
               <component>
                  <section ID="LINK_af75ba85-32e9-41f4-a03d-ba159b8c2b82">
                     <id root="32feb900-c326-4aca-e063-6294a90ae143"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.1 Storage</title>
                     <text>
                        <paragraph>Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from moisture and humidity.</paragraph>
                        <paragraph/>
                        <paragraph>Keep out of reach of children.</paragraph>
                     </text>
                     <effectiveTime value="20160131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_438c9913-71b9-45a8-8cea-b3a6d546947c">
               <id root="7bbfb226-212a-6d24-e053-2991aa0a71ca"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered">
                     <item>Patients should be informed that oxybutynin may produce angioedema that could result in life threatening airway obstruction. Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience swelling of the tongue, edema of the laryngopharynx, or difficulty breathing.</item>
                     <item>Patients should be informed that anticholinergic (antimuscarinic) agents such as Oxybutynin chloride extended-release tablets, may produce clinically significant adverse reactions related to anticholinergic activity such as:
	
   <list listType="unordered">
                           <item>Urinary retention and constipation</item>
                           <item>Heat prostration due to decreased sweating. Heat prostration can occur when anticholinergic medicines are administered in the presence of high environmental temperature.</item>
                        </list>
                     </item>
                     <item>Patients should be informed that anticholinergic medicines such as Oxybutynin chloride extended-release tablets may produce drowsiness (somnolence), dizziness or blurred vision. Patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until Oxybutynin chloride extended-release tablets effects have been determined.</item>
                     <item>Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as Oxybutynin chloride extended-release tablets.</item>
                     <item>Patients should be informed that Oxybutynin chloride extended-release tablets should be swallowed whole with the aid of liquids. Patients should not chew, divide, or crush tablets. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.</item>
                     <item>Oxybutynin chloride extended-release tablets should be taken at approximately the same time each day.</item>
                  </list>
                  <paragraph>For more information call 1-855-361-3993.</paragraph>
               </text>
               <effectiveTime value="20160131"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9048d19b-2134-4092-acd6-170a8d24fdae">
               <id root="32fec5ec-955a-b606-e063-6394a90a7025"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>AvKARE                                                                                                                                                                                                        Pulaski, TN 38478</paragraph>
                  <paragraph>Mfg. Rev. 05/23                                                                                                                                                                              </paragraph>
                  <paragraph>AV Rev. 03/25(M)                                                                                                                                                                          </paragraph>
                  <paragraph>AvPAK</paragraph>
               </text>
               <effectiveTime value="20161005"/>
            </section>
         </component>
         <component>
            <section ID="LINK_bef8abb9-f999-4b70-bec5-fb9c1f4898c9">
               <id root="32febf3b-03a1-4c47-e063-6294a90a3d1c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_32feca37-3061-6958-e063-6294a90aaea3"/>
                  </paragraph>
               </text>
               <effectiveTime value="20161015"/>
               <component>
                  <observationMedia ID="img_32feca37-3061-6958-e063-6294a90aaea3">
                     <text>1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="627-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0d408a93-e411-4822-a9ac-289cdbb9e23f">
               <id root="32fecbe0-b8e5-b2a3-e063-6394a90a2db0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_32fec6b3-f123-b5b6-e063-6394a90ab77d"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20161015"/>
               <component>
                  <observationMedia ID="img_32fec6b3-f123-b5b6-e063-6394a90ab77d">
                     <text>1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="628-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_15c9b7df-01c9-405e-8d48-7866e69c6f3f">
               <id root="32fecd5b-7cb9-bb21-e063-6394a90ae8cc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_32feccfd-52b7-82c2-e063-6394a90af9bb"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20161015"/>
               <component>
                  <observationMedia ID="img_32feccfd-52b7-82c2-e063-6394a90af9bb">
                     <text>1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="629-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>